I’m skeptical of RT001, but hyperhydrosis is probably the best indication for it. (I don’t think a topical product will work well in cosmetic applications.)
If it were up to me, RVNC would drop RT001 completely and focus on RT002, the (long-acting) injected botulinum toxic that figures to be strong competition for Botox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.